Leuprorelin 1-month depot as neoadjuvant therapy for prostate cancer

Urologia Internationalis

Volumn 60, Issue SUPPL.2, 1998, Pages 11-17

  Prezioso, Domenico ^a,c   Lotti, Tullio ^a   Montironi, Rodolfo ^b   Polito, Mario ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c NONE   (Italy)

Author keywords

Histological evaluation; Neoadjuvant hormonal treatment; Prostate cancer specimen; Radical prostatectomy

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYPROTERONE ACETATE; LEUPRORELIN;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HORMONAL THERAPY; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

EID: 0031956891     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000056546     Document Type: Conference Paper

References (27)

1. Boyle P: Prostate cancer 2000: Evolution of an epidemic of unknown origin; in Denis L (ed): Prostate Cancer 2000. Heidelberg, Springer, 1994. pp 5-11.
2. Parkin DM, Pisani P, Ferlay J: Worldwide burden of cancer, in: Biennial Report 1994-95. Lyon, IARC, 1995, pp 14-15.
3. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics 1996. CA 1996;46:5-27.
4. Wingo PA, Troy T, Bolden S: Cancer statistics 1995. CA 1995;45:8
5. Gibbons RP, Correa RJ, Brannen GE: Total prostatectomy for clinically localized prostate cancer. Long-term results. J Urol 1989;141:564-566.
6. Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994;152:1826-1830.
7. Zincke H, Oesterling JE, Blute ML: Long-term (15 years) results after radical prostatectomy for clinically localized prostate cancer. J Urol 1994;152:1850-1857.
8. Catalona WJ, Smith DS: 5 years tumor recurrence rates after anatomical radical prostatectomy for prostate cancer. J Urol 1994;152:1837-1842.
9. Trapasso JG, deKernion JB, Smith RB: Incidence and significance of detectable levels of serum PSA after radical prostatectomy. J Urol 1994;152:1821-1825.
10. Epstein JI, Pizof J, Walsh PC: Correlation of pathologic findings with progression after radical prostatectomy. Cancer 1993;71:3582-3593.
11. Ohori M, Wheeler TM, Katten MW: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995;154:1818-1824.
12. Mukamel E, Hannah J, Barbaric Z, deKernion JB: The value of CT scan and MRI in staging prostatic carcinoma: Comparison with the clinical and histological staging. J Urol 1986;136:1231-1233.
13. Stamey TA, Kabalin JN, McNeal JE: Prostate-specific antigen in the diagnosis and treatment of the adenocarinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989;141:1076-1083.
14. Katz AE, Olsson CA, Raffo AJ: Molecular staging of prostate cancer with the use of RT-PCR assay Urology 1994;43:765-775.
15. Rosen MA, Goldstone L, Lapin S: Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 1992;148:331-337.
16. Van Den Ouden D, Bentvelsen FM, Boeve ER: Positive margins after radical prostatectomy correlation with local recurrence and distant progression. Br J Urol 1993;72:489-494.
17. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical prostatectomy: Results at 10 years. J Urol 1994;152:1831-1836.
18. Garnick MB, Fair WR: Prostate cancer: Emerging concepts. Part 1. Ann Intern Med 1996;125:118-125.
19. Vallet BS: Radical perineal prostatectomy subsequent of bilateral orchidectomy. Del Med J 1994;16:19-21.
20. Soloway MS, Hachiya TS, Ruiz H: Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate specific antigen. World J Urol 1993;11.221-226.
21. Fair WR, Aprikian AG, Cohen D: Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clin Invest Med 1993;16:516-522.
22. Solomon MH, McHugh TA, Dorr RP: Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy. Clin Invest Med 1993;16:532-538.
23. Pummer K, Crawford ED, Daneshgary F: Hormonal pretreatment does not affect the final pathological stage m locally advanced prostate cancer. Urology 1994;44:38-41.
24. Haggman M, Hellstrom M, Aus G: Neoadjuvant GnRH-agonist treatment (triptorelin and cyproterone acetate for flare protection) and total prostatectomy. Eur Urol 1993;24:456-460.
25. Labrie F, Cusal L, Gomez JL, Diamond P, Juburu R, Lemay M, Tetu B, Fradet Y, Candas B: Downstaging of early prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 1994;44:29-37.
26. Soloway M, Sharifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2BNxM0) prostate cancer. J Urol 199 5;154:424-428.
27. Abbas F, Scardino PT. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol Clin North Am 1996;23:586-604.